



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
21.02.2018 Bulletin 2018/08

(45) Date of publication and mention
of the grant of the patent:
20.12.2017 Bulletin 2017/51

(21) Application number: **08760496.3**

(22) Date of filing: **04.06.2008**

(51) Int Cl.:
C07D 207/12^(2006.01) A61K 31/40^(2006.01)
A61P 25/00^(2006.01)

(86) International application number:
PCT/EP2008/056915

(87) International publication number:
WO 2008/148801 (11.12.2008 Gazette 2008/50)

(54) **DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL
CATECHOLAMINERGIC NEUROTRANSMISSION**

DISUBSTITUIERTE PHENYLPYRROLIDINE ALS MODULATOREN DER KORTIKALEN
KATECHOLAMINERGEN NEUROTRANSMISSION

PHÉNYLPYRROLIDINES DISUBSTITUÉES EN TANT QUE MODULATEURS DE LA
NEUROTRANSMISSION CATÉCHOLAMINERGIQUE CORTICALE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

(30) Priority: **05.06.2007 SE 0701387**
05.06.2007 US 941994 P

(43) Date of publication of application:
24.02.2010 Bulletin 2010/08

(73) Proprietor: **Integrative Research Laboratories
Sweden AB**
413 46 Göteborg (SE)

(72) Inventors:
• **SONESSON, Clas**
S-413 46 Göteborg (SE)
• **SWANSON, Lars**
S-413 46 Göteborg (SE)
• **PETTERSSON, Fredrik**
S-413 46 Göteborg (SE)
• **WATERS, Nicholas**
S-413 46 Göteborg (SE)

• **WATERS, Susanna**
S-413 46 Göteborg (SE)

(74) Representative: **Valea AB**
Anna Lindhs Plats 4
211 19 Malmö (SE)

(56) References cited:
WO-A-92/18475 WO-A-2005/121092
US-A- 3 118 907

• **WILLIAM A. GOULD ET AL.: "Pyrrolidines. IX.
3-Aryl-3-pyrrolidinols" JOURNAL OF MEDICINAL
CHEMISTRY., vol. 7, no. 1, 1964, pages 60-67,
XP002505965 USAMERICAN CHEMICAL
SOCIETY. WASHINGTON. cited in the application**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **SONESSON C ET AL: "SUBSTITUTED (S)-PHENYLPYPERIDINES AND RIGID CONGENERS AS PREFERENTIAL DOPAMINE AUTORECEPTOR ANTAGONISTS: SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS" JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 37, no. 17, 1 January 1994 (1994-01-01), pages 2735-2753, XP000925302 ISSN: 0022-2623 cited in the application**
- **SONESSON C ET AL: "Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 7, no. 3, 4 February 1997 (1997-02-04), pages 241-246, XP004136001 ISSN: 0960-894X cited in the application**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification